Zelira Therapeutics Advances Key Cannabis Programs

Zelira Therapeutics Ltd. (AU:ZLD) has released an update.

Zelira Therapeutics reports significant progress in Q3 FY2024, with key developments in their HOPE® Autism Spectrum Disorder program, including receiving the second tranche of SPV funding and advancing FDA trial processes. The company also secured a substantial R&D Tax Incentive refund and is on track to reformulate Zenivol® into a capsule, aiming for completion between late 2024 and early 2025.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.